Similar articles

• Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

  Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W. Hillmen P, et al. Am J Hematol. 2010 Aug;85(8):553-9. doi: 10.1002/ajh.21757. Am J Hematol. 2010. PMID: 20658586 Clinical Trial.
• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

  Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Rother RP, et al. Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344. Nat Biotechnol. 2007. PMID: 17989688
• Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.

  Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G. Hillmen P, et al. Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280. Am J Hematol. 2016. PMID: 26690023 No abstract available.
• [Eculizumab in paroxysmal nocturnal hemoglobinuria].

  Socié G, Varoqueaux N, Peffault de Latour R. Socié G, et al. Med Sci (Paris). 2009 Dec;25(12):1126-9. doi: 10.1051/medsci/200925121126. Med Sci (Paris). 2009. PMID: 20035691 Review. French.
• Drugs that inhibit complement.

  Schrezenmeier H, Höchsmann B. Schrezenmeier H, et al. Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13. Transfus Apher Sci. 2012. PMID: 22169380 Review.